CQS Cayman’s Pfizer PFE Stock Holding History

CQS Cayman’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-10,540	Closed	-$335K	–	190
2015 Q2	$335K	Buy	+10,540	New	+$344K	0.02%	165

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CQS Cayman's PFE Position: Q3 2015 in Review

CQS Cayman sold out of Pfizer (PFE) in Q3 2015, closing a stake of 10,540 shares — an estimated $335K sold.

CQS Cayman first reported a position in PFE in Q2 2015 and held it in 1 quarter. The position peaked at $335K in Q2 2015. 1,879 funds tracked by Wall St. Rank hold PFE as of Q3 2015.

CQS Cayman reported no remaining Pfizer position as of Q3 2015 after selling out during the quarter.
CQS Cayman sold 10,540 Pfizer shares in Q3 2015, an estimated $335K.
CQS Cayman first reported a position in Pfizer in Q2 2015 and held it in 1 quarter.
CQS Cayman's Pfizer position peaked at $335K in Q2 2015.
1,879 funds tracked by Wall St. Rank held Pfizer as of Q3 2015.

Based on CQS Cayman's 13F filing for Q3 2015, filed 30 Oct 2015.